Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.21 AUD
Change Today -0.005 / -2.38%
Volume 64.8K
As of 2:10 AM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

pharmaxis ltd (PXS) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/18/15 - A$0.27
52 Week Low
10/30/14 - A$0.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PHARMAXIS LTD (PXS)

Related News

No related news articles were found.

pharmaxis ltd (PXS) Related Businessweek News

No Related Businessweek News Found

pharmaxis ltd (PXS) Details

Pharmaxis Ltd, a specialty pharmaceutical company, engages in the research, development, and commercialization of human healthcare products for the treatment and management of respiratory and other chronic diseases worldwide. Its lead product and product candidates are used for the diagnosis and treatment of chronic respiratory diseases, including asthma, cystic fibrosis, and chronic obstructive pulmonary disease (COPD), including bronchiectasis and chronic bronchitis, and other chronic and acute pulmonary conditions. The company offers Aridol lung function test, which is designed to assist physicians in the assessment of asthma by identifying and measuring airway hyperresponsiveness; and Bronchitol, a drug designed to reduce the amount of mucus build-up in the lungs of patients suffering from chronic respiratory conditions. Its early product development pipeline includes orbital dry powder inhaler that delivers drug doses to the lungs; Lysyl Oxidase Like 2 (LOXL-2) inhibitors for the treatment of fibrosis; PXS64/25 targeting lung fibrosis; ASM8 targeting severe asthma; and PXS TPI1100 for the treatment candidate for COPD. The company has research collaboration with Synairgen plc to develop a selective inhibitor to the lysyl oxidase type 2 enzyme to treat idiopathic pulmonary fibrosis, a lung disease. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.

Founded in 1998

pharmaxis ltd (PXS) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: A$725.6K
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: A$566.8K
Head of Drug Discovery
Total Annual Compensation: A$442.9K
Medical Director and Member of Disclosure Com...
Total Annual Compensation: A$423.5K
Compensation as of Fiscal Year 2015.

pharmaxis ltd (PXS) Key Developments

Synairgen plc and Pharmaxis Ltd Enter into Research Collaboration to Develop Selective Inhibitor to the Lysyl Oxidase Type 2

Synairgen plc and Pharmaxis Ltd. announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF). IPF affects in the region of 100,000 people in the US. Current products are expected to produce global revenues in excess of $1.1 billion by 2017. The LOXL2 enzyme is being targeted because it is known to promote scar tissue which hardens and irreparably damages the lungs of IPF patients. It is hoped that the inhibition of LOXL2 will slow the build-up of scar tissue and improve survival rates that are worse than for many cancers.

Pharmaxis Ltd. Reports Unaudited Earnings Results for the Fourth Quarter and Year Ended June 30, 2015

Pharmaxis Ltd. reported unaudited earnings results for the fourth quarter and year ended June 30, 2015. For the quarter, the company reported revenue of AUD 43,712,000 against AUD 2,883,000 a year ago. Net income before tax was AUD 31,834,000 against net loss before tax of AUD 21,165,000 a year ago. Net profit after tax was AUD 31,887,000 against net loss after tax of AUD 21,159,000 a year ago. For the year, the company reported revenue of AUD 60,247,000 against AUD 10,486,000 a year ago. Net income before tax was AUD 19,508,000 against net loss before tax of AUD 51,715,000 a year ago. Net profit after tax was AUD 19,466,000 against net loss after tax of AUD 51,818,000 a year ago.

Boehringer Ingelheim Acquires PXS4728A from Pharmaxis

Boehringer Ingelheim GmbH has exercised its option and acquired the investigational drug PXS4728A from Pharmaxis Ltd. The drug PXS4728A will be used for the treatment of the liver-related condition nonalcoholic steatohepatitis (NASH) and to prevent its consequences. Under the terms of the transaction, Pharmaxis will receive an upfront payment of EUR 27.5 million and, subject to the continuing successful development and commercialization of the PXS4728A program, the following payments: up to a total of EUR 55 million in development milestone payments tied to the commencement of phase 2 and 3 clinical trials; up to a total of EUR 140 million in regulatory milestone payments upon filing of applications for marketing approval and receipt of regulatory and pricing approvals for a PXS4728A program product in the pharmaceutical market for the first indication; additional milestone payments similar in total to those set out above upon achievement of the same development and regulatory milestone events by a PXS4728A program product for a second indication; earn-out payments on annual net sales of PXS4728A program products at tiered percentages starting in the high single digits; and commercialization milestone payments upon achievement of specified levels of annual net sales of PXS4728A program products. Boehringer has also acquired other SSAO/VAP-1 inhibitor molecules related to PXS4728A and associated patents.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PXS:AU A$0.21 AUD -0.005

PXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PXS.
View Industry Companies

Industry Analysis


Industry Average

Valuation PXS Industry Range
Price/Earnings 3.2x
Price/Sales 1.3x
Price/Book 1.7x
Price/Cash Flow 2.8x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMAXIS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at